JP2022523702A - トランス-4-ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法 - Google Patents
トランス-4-ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法 Download PDFInfo
- Publication number
- JP2022523702A JP2022523702A JP2021543502A JP2021543502A JP2022523702A JP 2022523702 A JP2022523702 A JP 2022523702A JP 2021543502 A JP2021543502 A JP 2021543502A JP 2021543502 A JP2021543502 A JP 2021543502A JP 2022523702 A JP2022523702 A JP 2022523702A
- Authority
- JP
- Japan
- Prior art keywords
- cycloalkyl
- alkyl
- disease
- mitochondrial
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012190 activator Substances 0.000 title claims abstract description 93
- 101000957747 Drosophila melanogaster Transmembrane GTPase Marf Proteins 0.000 title claims abstract description 38
- DQLUTNSRYKTETG-HAQNSBGRSA-N O[C@@H]1CC[C@H](CC1)NC1=CC=CC=C1 Chemical compound O[C@@H]1CC[C@H](CC1)NC1=CC=CC=C1 DQLUTNSRYKTETG-HAQNSBGRSA-N 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 160
- 201000010099 disease Diseases 0.000 claims abstract description 99
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 97
- 239000000203 mixture Substances 0.000 claims abstract description 82
- -1 6-phenylhexaneamide derivative small molecule Chemical class 0.000 claims abstract description 73
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 208000035475 disorder Diseases 0.000 claims abstract description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 114
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 104
- 238000000034 method Methods 0.000 claims description 89
- 208000011580 syndromic disease Diseases 0.000 claims description 63
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 51
- 125000001072 heteroaryl group Chemical group 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 46
- 125000000623 heterocyclic group Chemical group 0.000 claims description 45
- 125000003118 aryl group Chemical group 0.000 claims description 44
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 43
- 230000004927 fusion Effects 0.000 claims description 42
- 208000014674 injury Diseases 0.000 claims description 36
- 229910052731 fluorine Inorganic materials 0.000 claims description 31
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 30
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 29
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 28
- 208000014644 Brain disease Diseases 0.000 claims description 28
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 28
- 201000001119 neuropathy Diseases 0.000 claims description 28
- 208000032274 Encephalopathy Diseases 0.000 claims description 27
- 239000000460 chlorine Chemical group 0.000 claims description 27
- 230000006378 damage Effects 0.000 claims description 27
- 230000007823 neuropathy Effects 0.000 claims description 27
- 208000027418 Wounds and injury Diseases 0.000 claims description 26
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 21
- 210000003169 central nervous system Anatomy 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 230000000626 neurodegenerative effect Effects 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 238000002512 chemotherapy Methods 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 230000004064 dysfunction Effects 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- 208000023105 Huntington disease Diseases 0.000 claims description 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 208000018737 Parkinson disease Diseases 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 16
- 125000006552 (C3-C8) cycloalkyl group Chemical class 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 15
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 15
- 210000004556 brain Anatomy 0.000 claims description 15
- 229910052794 bromium Inorganic materials 0.000 claims description 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 15
- 230000002490 cerebral effect Effects 0.000 claims description 15
- 230000001771 impaired effect Effects 0.000 claims description 15
- 150000002825 nitriles Chemical class 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 150000003462 sulfoxides Chemical class 0.000 claims description 15
- 229930192474 thiophene Natural products 0.000 claims description 15
- 208000012661 Dyskinesia Diseases 0.000 claims description 14
- SUKXKLNDBLNTSW-QAQDUYKDSA-N O[C@@H]1CC[C@H](CC1)NC(CCCCCC1=CC=CC=C1)=O Chemical compound O[C@@H]1CC[C@H](CC1)NC(CCCCCC1=CC=CC=C1)=O SUKXKLNDBLNTSW-QAQDUYKDSA-N 0.000 claims description 14
- 230000004899 motility Effects 0.000 claims description 14
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims description 14
- 125000006655 (C3-C8) heteroaryl group Chemical class 0.000 claims description 13
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 13
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 13
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 13
- 208000006011 Stroke Diseases 0.000 claims description 13
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 12
- 208000021642 Muscular disease Diseases 0.000 claims description 12
- 201000009623 Myopathy Diseases 0.000 claims description 12
- 230000002496 gastric effect Effects 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 12
- 230000032258 transport Effects 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 206010015037 epilepsy Diseases 0.000 claims description 10
- 230000002232 neuromuscular Effects 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 208000020431 spinal cord injury Diseases 0.000 claims description 10
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 9
- 238000013467 fragmentation Methods 0.000 claims description 9
- 238000006062 fragmentation reaction Methods 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 9
- 206010003805 Autism Diseases 0.000 claims description 8
- 208000020706 Autistic disease Diseases 0.000 claims description 8
- 206010011878 Deafness Diseases 0.000 claims description 8
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
- 208000035177 MELAS Diseases 0.000 claims description 8
- 208000035172 MERRF Diseases 0.000 claims description 8
- 208000030768 Optic nerve injury Diseases 0.000 claims description 8
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 claims description 8
- 230000003412 degenerative effect Effects 0.000 claims description 8
- 208000016354 hearing loss disease Diseases 0.000 claims description 8
- 201000006938 muscular dystrophy Diseases 0.000 claims description 8
- 208000012584 pre-descemet corneal dystrophy Diseases 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 201000007737 Retinal degeneration Diseases 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 7
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 7
- 230000003155 kinesthetic effect Effects 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 208000004130 Blepharoptosis Diseases 0.000 claims description 6
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 6
- 208000024658 Epilepsy syndrome Diseases 0.000 claims description 6
- 208000002877 Epileptic Syndromes Diseases 0.000 claims description 6
- 206010015995 Eyelid ptosis Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 231100000895 deafness Toxicity 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- 208000006443 lactic acidosis Diseases 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 201000003004 ptosis Diseases 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- FPOQQFPVMGNKJM-UHFFFAOYSA-N 6-phenylhexanamide Chemical class NC(=O)CCCCCC1=CC=CC=C1 FPOQQFPVMGNKJM-UHFFFAOYSA-N 0.000 claims description 5
- WTLOEKALPQSRQP-SHTZXODSSA-N C1[C@@H](CC[C@@H](NC(=O)CCCCOC2=CC=CC=C2)C1)O Chemical compound C1[C@@H](CC[C@@H](NC(=O)CCCCOC2=CC=CC=C2)C1)O WTLOEKALPQSRQP-SHTZXODSSA-N 0.000 claims description 5
- 208000025962 Crush injury Diseases 0.000 claims description 5
- SUKXKLNDBLNTSW-CALCHBBNSA-N O[C@H]1CC[C@H](CC1)NC(CCCCCC1=CC=CC=C1)=O Chemical compound O[C@H]1CC[C@H](CC1)NC(CCCCCC1=CC=CC=C1)=O SUKXKLNDBLNTSW-CALCHBBNSA-N 0.000 claims description 5
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 5
- 230000001272 neurogenic effect Effects 0.000 claims description 5
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 5
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 5
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 5
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000010189 intracellular transport Effects 0.000 claims description 4
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical group [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- VLTXLMXITFPPQX-UHFFFAOYSA-N C1(CC1)C=1N(C(=NN=1)CCCNC(=O)NC1C(CCCC1)C)C1=CC=CC=C1 Chemical compound C1(CC1)C=1N(C(=NN=1)CCCNC(=O)NC1C(CCCC1)C)C1=CC=CC=C1 VLTXLMXITFPPQX-UHFFFAOYSA-N 0.000 claims description 3
- 150000003869 acetamides Chemical class 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- HRXYOIQACQDULT-UHFFFAOYSA-N C1(CC1)C=1N(C(=NN=1)OCCNC(=O)NC1C(CCCC1)C)C1=CC=CC=C1 Chemical compound C1(CC1)C=1N(C(=NN=1)OCCNC(=O)NC1C(CCCC1)C)C1=CC=CC=C1 HRXYOIQACQDULT-UHFFFAOYSA-N 0.000 claims description 2
- 208000018380 Chemical injury Diseases 0.000 claims description 2
- 208000028782 Hereditary disease Diseases 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 20
- 230000003213 activating effect Effects 0.000 abstract description 9
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 101001019367 Homo sapiens Mitofusin-1 Proteins 0.000 abstract 1
- 102100034715 Mitofusin-1 Human genes 0.000 abstract 1
- JKCGHZSDZKIARJ-BDWYFLKXSA-N O[C@@H]1CC[C@H](CC1)C(C(=O)N)CCCCC1=CC=CC=C1 Chemical class O[C@@H]1CC[C@H](CC1)C(C(=O)N)CCCCC1=CC=CC=C1 JKCGHZSDZKIARJ-BDWYFLKXSA-N 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 49
- 210000003470 mitochondria Anatomy 0.000 description 32
- 208000015122 neurodegenerative disease Diseases 0.000 description 32
- 238000011282 treatment Methods 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- 230000004770 neurodegeneration Effects 0.000 description 24
- 210000002569 neuron Anatomy 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 201000008990 Charcot-Marie-Tooth disease type 2A1 Diseases 0.000 description 22
- SUKXKLNDBLNTSW-UHFFFAOYSA-N N-(4-hydroxycyclohexyl)-6-phenylhexanamide Chemical compound OC1CCC(CC1)NC(CCCCCC1=CC=CC=C1)=O SUKXKLNDBLNTSW-UHFFFAOYSA-N 0.000 description 20
- 150000003384 small molecules Chemical class 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 206010033799 Paralysis Diseases 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 238000011069 regeneration method Methods 0.000 description 12
- 230000008439 repair process Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000001537 neural effect Effects 0.000 description 11
- 230000008929 regeneration Effects 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010003591 Ataxia Diseases 0.000 description 8
- 208000028389 Nerve injury Diseases 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010028289 Muscle atrophy Diseases 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 201000000585 muscular atrophy Diseases 0.000 description 7
- 230000008764 nerve damage Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 6
- 208000010641 Tooth disease Diseases 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000002260 anti-inflammatory agent Substances 0.000 description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 description 6
- 230000037444 atrophy Effects 0.000 description 6
- 210000003050 axon Anatomy 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000026326 mitochondrial transport Effects 0.000 description 6
- 230000020763 muscle atrophy Effects 0.000 description 6
- 208000034656 Contusions Diseases 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 208000001089 Multiple system atrophy Diseases 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 150000003973 alkyl amines Chemical class 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000009519 contusion Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 208000021090 palsy Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010063491 Herpes zoster oticus Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000034800 Leukoencephalopathies Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 201000011349 geniculate herpes zoster Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 210000001589 microsome Anatomy 0.000 description 4
- 230000004898 mitochondrial function Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 238000013149 parallel artificial membrane permeability assay Methods 0.000 description 4
- 229920000333 poly(propyleneimine) Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001148 spastic effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000002033 Myoclonus Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 206010031127 Orthostatic hypotension Diseases 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 201000003723 learning disability Diseases 0.000 description 3
- 125000005647 linker group Chemical class 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000007625 mitochondrial abnormality Effects 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 230000003961 neuronal insult Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- OWUXUXDKUOFZOQ-UHFFFAOYSA-N 1-(2-benzylsulfanylethyl)-3-(2-methylcyclohexyl)urea Chemical group CC1CCCCC1NC(=O)NCCSCC1=CC=CC=C1 OWUXUXDKUOFZOQ-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- RUVJFMSQTCEAAB-UHFFFAOYSA-M 2-[3-[5,6-dichloro-1,3-bis[[4-(chloromethyl)phenyl]methyl]benzimidazol-2-ylidene]prop-1-enyl]-3-methyl-1,3-benzoxazol-3-ium;chloride Chemical compound [Cl-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C(N(C1=CC(Cl)=C(Cl)C=C11)CC=2C=CC(CCl)=CC=2)N1CC1=CC=C(CCl)C=C1 RUVJFMSQTCEAAB-UHFFFAOYSA-M 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 2
- ZAMASFSDWVSMSY-UHFFFAOYSA-N 5-[[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy-2-methylphenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C(C)=CC=1OC1=NC=C(C(F)(F)F)C=C1Cl ZAMASFSDWVSMSY-UHFFFAOYSA-N 0.000 description 2
- JTXZPQIXIXYMDY-UHFFFAOYSA-N 6-phenylhexanoic acid Chemical compound OC(=O)CCCCCC1=CC=CC=C1 JTXZPQIXIXYMDY-UHFFFAOYSA-N 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 206010003101 Arnold-Chiari Malformation Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000025978 Athletic injury Diseases 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010008096 Cerebral atrophy Diseases 0.000 description 2
- 208000015321 Chiari malformation Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 206010009346 Clonus Diseases 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000020358 Learning disease Diseases 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000004983 Phantom Limb Diseases 0.000 description 2
- 206010056238 Phantom pain Diseases 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 208000021811 Sandhoff disease Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 2
- 208000020339 Spinal injury Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003882 axonal neuropathy Diseases 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 230000031857 establishment of mitochondrion localization Effects 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000021245 head disease Diseases 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000010852 mitochondrial transfer Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- NBAOBNBFGNQAEJ-UHFFFAOYSA-M tetramethylrhodamine ethyl ester perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 NBAOBNBFGNQAEJ-UHFFFAOYSA-M 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- DAUYIKBTMNZABP-UHFFFAOYSA-N thiophene-3-carboxamide Chemical compound NC(=O)C=1C=CSC=1 DAUYIKBTMNZABP-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000023697 ABri amyloidosis Diseases 0.000 description 1
- 208000017227 ADan amyloidosis Diseases 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 208000004438 Alien Hand Syndrome Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 108700033847 Alpha-Methylacyl-CoA Racemase Deficiency Proteins 0.000 description 1
- 208000032949 Alpha-thalassemia-intellectual disability syndrome linked to chromosome 16 Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 201000007848 Arts syndrome Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 208000004724 Ataxia neuropathy spectrum Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 208000033917 CACH syndrome Diseases 0.000 description 1
- 201000003551 CEDNIK syndrome Diseases 0.000 description 1
- 208000025480 CHILD syndrome Diseases 0.000 description 1
- 208000033418 CLN1 disease Diseases 0.000 description 1
- 208000033412 CLN10 disease Diseases 0.000 description 1
- 208000033528 CLN2 disease Diseases 0.000 description 1
- 208000033527 CLN3 disease Diseases 0.000 description 1
- 208000033436 CLN6 disease Diseases 0.000 description 1
- 208000033438 CLN7 disease Diseases 0.000 description 1
- 208000033549 CLN8 disease Diseases 0.000 description 1
- 208000016560 COFS syndrome Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010050389 Cerebral ataxia Diseases 0.000 description 1
- 208000031976 Channelopathies Diseases 0.000 description 1
- 201000006892 Charcot-Marie-Tooth disease type 1 Diseases 0.000 description 1
- 201000009009 Charcot-Marie-Tooth disease type 1A Diseases 0.000 description 1
- 208000035758 Charcot-Marie-Tooth disease type 2S Diseases 0.000 description 1
- 201000006868 Charcot-Marie-Tooth disease type 3 Diseases 0.000 description 1
- 201000010122 Charcot-Marie-Tooth disease type 5 Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010539 Congenital megacolon Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012676 Diabetic mononeuropathy Diseases 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 102100031675 DnaJ homolog subfamily C member 5 Human genes 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 241000004297 Draba Species 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000002403 Encephalocele Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000007223 Gerstmann syndrome Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 1
- 208000032006 Hereditary motor and sensory neuropathy type 5 Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000004592 Hirschsprung disease Diseases 0.000 description 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
- 101000845893 Homo sapiens DnaJ homolog subfamily C member 5 Proteins 0.000 description 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 description 1
- 101001018717 Homo sapiens Mitofusin-2 Proteins 0.000 description 1
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010053712 Hypersomnia-bulimia syndrome Diseases 0.000 description 1
- 208000008017 Hypohidrosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 description 1
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000028603 Interstitial lung disease specific to childhood Diseases 0.000 description 1
- 208000018650 Intervertebral disc disease Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 201000008178 Kleine-Levin syndrome Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 208000005870 Lafora disease Diseases 0.000 description 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
- 208000037795 Lethal ataxia with deafness and optic atrophy Diseases 0.000 description 1
- 208000019128 MacLeod syndrome Diseases 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000014844 Mitochondrial neurogastrointestinal encephalomyopathy Diseases 0.000 description 1
- 102100033703 Mitofusin-2 Human genes 0.000 description 1
- 108050004120 Mitofusin-2 Proteins 0.000 description 1
- 201000002983 Mobius syndrome Diseases 0.000 description 1
- 208000034167 Moebius syndrome Diseases 0.000 description 1
- 208000017281 Morvan syndrome Diseases 0.000 description 1
- 208000019896 Motor Skills disease Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000009433 Moyamoya Disease Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 208000012905 Myotonic disease Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010021592 Pantothenate kinase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 201000006880 Phelan-McDermid syndrome Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000022372 Reading disease Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 102000004431 Riboflavin transporter Human genes 0.000 description 1
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 201000003696 Sotos syndrome Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000035562 Wallenberg syndrome Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 201000002439 alpha thalassemia-intellectual disability syndrome type 1 Diseases 0.000 description 1
- 201000000673 alpha-methylacyl-CoA racemase deficiency Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 206010002512 anhidrosis Diseases 0.000 description 1
- 230000037001 anhydrosis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 208000030137 articulation disease Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 208000031375 autosomal dominant myotonia congenita Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000010353 central nervous system vasculitis Diseases 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 208000031406 ceroid lipofuscinosis, neuronal, 4 (Kufs type) Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- HISOCSRUFLPKDE-KLXQUTNESA-N cmt-2 Chemical compound C1=CC=C2[C@](O)(C)C3CC4C(N(C)C)C(O)=C(C#N)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O HISOCSRUFLPKDE-KLXQUTNESA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 208000011664 congenital factor XI deficiency Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 210000004714 cranial suture Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 229940124642 endogenous agent Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000007219 factor XI deficiency Diseases 0.000 description 1
- 206010016284 febrile convulsion Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000017723 hereditary motor and sensory neuropathy type 6 Diseases 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000057083 human MFN2 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000005891 hyperlucent lung Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000013094 juvenile primary lateral sclerosis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 208000004343 lateral medullary syndrome Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000001996 leukoencephalopathy with vanishing white matter Diseases 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000010034 metabolic health Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- FZTMEYOUQQFBJR-UHFFFAOYSA-M mitoTracker Orange Chemical compound [Cl-].C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC=C(CCl)C=C1 FZTMEYOUQQFBJR-UHFFFAOYSA-M 0.000 description 1
- 230000027829 mitochondrial depolarization Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000025608 mitochondrion localization Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000019382 nerve compression syndrome Diseases 0.000 description 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 201000007642 neuronal ceroid lipofuscinosis 1 Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000003018 neuroregenerative effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000013651 non-24-hour sleep-wake syndrome Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 108020001053 riboflavin transporter Proteins 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 102220081739 rs863224069 Human genes 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000003172 sustentacular cell Anatomy 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003273 vestibular nerve Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 208000015897 writing disease Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Description
本願は、2019年1月28日出願の米国仮出願第62/797,513号及び2019年12月17日出願の米国仮出願第62/949,060号の優先権を主張する。
のうちの1つであり得る。
式中、R1は、非置換、一置換又は多置換のC3-8シクロアルキル、C3-8ヘテロアリール、C3-8アリール又はC3-8ヘテロシクリルである、条項1に記載の方法。
である、条項1~4のいずれか条項に記載の方法。
Zは、シクロアルキル、ヘテロシクロアルキル、アリール又はヘテロアリールであり、
R2及びR3は、独立して、H、F、アルキル及びC3-7シクロアルキルから選択されるか、又はR2とR3とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
R4及びR5は、独立して、H、F、アルキル及びC3-7シクロアルキルから選択されるか、又はR4とR5とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
Yは、O、CR6R7、CR8=CR9、三重結合、シクロアルキル、ヘテロシクロアルキル、アリール、ヘテロアリール、NR8、S、SO2、SONR9、-NR9SO2-、-NR8CO-、-CONR8-又は-NR8CONR9-であり、
R6は、H、F、アルキル又はシクロアルキルであり、R7は、H、F、アルキル又はシクロアルキルであるか、又はR6とR7とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
R8は、H、アルキル又はC3-7シクロアルキルであり、
R9は、H、アルキル又はC3-7シクロアルキルであり、
oは、0、1、2、3、4又は5であり、
pは、0又は1であり、
qは、0、1、2、3、4又は5であり、oが、1以上であるとき、Y=NR8、S、SO2、SONR9、-NR9SO2-、-NR8CO-、-CONR8-、-NR8CONR9-であり、o+p+qの合計は、3以上又は7以下である、
式IIの化合物又はその薬学的に許容され得る塩。
Yが、O、CR6R7、シクロアルキル又はアリールであり、
R2、R3、R4、R5、R6、R7及びR8が、独立して、H及びアルキルから選択され、oが、0、1、2、3、4又は5であり、
pが、0又は1であり、
qが、0、1、2、3、4又は5であり、
oが、1以上であるとき、Xは、S又はSO2であり、
o+p+qの合計は、3以上又は7以下である、
条項6に記載の化合物又はその薬学的に許容され得る塩。
Yが、O、CH2又はシクロアルキルであり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、
R9が、H、アルキル及びC3-7シクロアルキルであり、
oが、0、1、2、3、4又は5であり、
pが、0又は1であり、
qが、0、1、2、3、4又は5であり、
oが、1以上であるとき、Xは、S又はSO2であり、
o+p+qの合計は、3以上又は5以下である、
条項6~7のいずれかに記載の化合物又はその薬学的に許容され得る塩。
Yが、シクロプロピル又はシクロブチルであり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、
R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
oが、0、1、2又は3であり、
pが、1であり、
qが、0、1、2又は3であり、
o+p+qの合計は、3以上又は5以下である、
条項6~8のいずれかに記載の化合物又はその薬学的に許容され得る塩。
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
条項6~9のいずれかに記載の化合物又はその薬学的に許容され得る塩。
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
条項6~10のいずれかに記載の化合物又はその薬学的に許容され得る塩。
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
R10が、独立して、アルキル又はC3-7シクロアルキルから選択され、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
条項6~11のいずれかに記載の化合物又はその薬学的に許容され得る塩。
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
R10が、アルキル又はC3-7シクロアルキルであり、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
条項6~12のいずれかに記載の化合物又はその薬学的に許容され得る塩。
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、
R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又は
R8とR9とが一体となって、C3-7シクロアルキルを形成し、
R10が、アルキル又はC3-7シクロアルキルであり、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
条項6~13のいずれかに記載の化合物又はその薬学的に許容され得る塩。
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
R10が、アルキル又はC3-7シクロアルキルであり、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
条項6~14のいずれかに記載の化合物又はその薬学的に許容され得る塩。
である、条項6~15のいずれかに記載の化合物又はその薬学的に許容され得る塩。
である、条項6~15のいずれかに記載の化合物又はその薬学的に許容され得る塩。
Zは、シクロアルキル、ヘテロシクロアルキル、アリール又はヘテロアリールであり、
R2及びR3は、独立して、H、F、アルキル及びC3-7シクロアルキルから選択されるか、又はR2とR3とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
R4及びR5は、独立して、H、F、アルキル及びC3-7シクロアルキルから選択されるか、又はR4とR5とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
Yは、O、CR6R7、CR8=CR9、三重結合、シクロアルキル、ヘテロシクロアルキル、アリール、ヘテロアリール、NR8、S、SO2、SONR9、-NR9SO2-、-NR8CO-、-CONR8-又は-NR8CONR9-であり、
R6は、H、F、アルキル又はシクロアルキルであり、R7は、H、F、アルキル又はシクロアルキルであるか、又はR6とR7とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
R8は、H、アルキル又はC3-7シクロアルキルであり、
R9は、H、アルキル又はC3-7シクロアルキルであり、
oは、0、1、2、3、4又は5であり、
pは、0又は1であり、
qは、0、1、2、3、4又は5であり、oが、1以上であるとき、Y=NR8、S、SO2、SONR9、-NR9SO2-、-NR8CO-、-CONR8-、-NR8CONR9-であり、o+p+qの合計は、3以上又は7以下である、
方法。
ミトコンドリアの融合、健康状態又は輸送が損なわれている慢性神経変性状態、
マイトフュージン1(MFN1)又はマイトフュージン2(MFN2)の機能不全に関連する疾患又は障害、
ミトコンドリアの断片化、機能不全又は運動不全に関連する疾患、
シャルコー・マリー・トゥース病、筋萎縮性側索硬化症、ハンチントン病、アルツハイマー病、パーキンソン病などの変性神経筋状態、
遺伝性運動感覚性ニューロパチー、自閉症、常染色体優性視神経萎縮症(ADOA)、筋ジストロフィー、ルー・ゲーリッグ病、癌、ミトコンドリアミオパチー、聴覚消失を伴う真性糖尿病(DAD)、レーベル遺伝性視神経症(LHON)、リー症候群、亜急性硬化性脳症、ニューロパチー・運動失調・網膜色素変性症・眼瞼下垂(NARP)、筋神経胃腸管性脳症(MNGIE)、赤色ぼろ線維・ミオクローヌスてんかん症候群(MERRF)、ミトコンドリアミオパチー・脳筋症・乳酸アシドーシス・脳卒中様症状(MELAS)、mtDNA枯渇、ミトコンドリア神経性胃腸管系脳筋症(MNGIE)、自律神経障害性ミトコンドリアミオパチー、ミトコンドリアチャネル病又はピルビン酸脱水素酵素複合体欠損症(PDCD/PDH)、
糖尿病性ニューロパチー、
化学療法誘発性末梢神経障害、並びに/又は
挫滅傷、脊髄傷害(SCI)、外傷性脳傷害、脳卒中、視神経傷害、及び軸索切断を伴う関連状態
のうちのいずれか1つ又は組み合わせから選択される、条項1~5又は18のいずれかに記載の方法。
から選択されないという条件の、条項1~5、18又は19のいずれかに記載の方法。
ミトコンドリアの融合、健康状態又は輸送が損なわれている慢性神経変性状態、
マイトフュージン1(MFN1)又はマイトフュージン2(MFN2)の機能不全に関連する疾患又は障害、
ミトコンドリアの断片化、機能不全又は運動不全に関連する疾患、
シャルコー・マリー・トゥース病、筋萎縮性側索硬化症、ハンチントン病、アルツハイマー病、パーキンソン病などの変性神経筋状態、
遺伝性運動感覚性ニューロパチー、自閉症、常染色体優性視神経萎縮症(ADOA)、筋ジストロフィー、ルー・ゲーリッグ病、癌、ミトコンドリアミオパチー、聴覚消失を伴う真性糖尿病(DAD)、レーベル遺伝性視神経症(LHON)、リー症候群、亜急性硬化性脳症、ニューロパチー・運動失調・網膜色素変性症・眼瞼下垂(NARP)、筋神経胃腸管性脳症(MNGIE)、赤色ぼろ線維・ミオクローヌスてんかん症候群(MERRF)、ミトコンドリアミオパチー・脳筋症・乳酸アシドーシス・脳卒中様症状(MELAS)、mtDNA枯渇、ミトコンドリア神経性胃腸管系脳筋症(MNGIE)、自律神経障害性ミトコンドリアミオパチー、ミトコンドリアチャネル病又はピルビン酸脱水素酵素複合体欠損症(PDCD/PDH)、
糖尿病性ニューロパチー、
化学療法誘発性末梢神経障害、並びに/又は
挫滅傷、脊髄傷害、外傷性脳傷害、脳卒中、視神経傷害、及び軸索切断を伴う関連状態
と診断されている又は有すると疑われる、条項22に記載の方法。
Claims (24)
- 末梢神経系(PNS)又は中枢神経系(CNS)の遺伝性障害、物理的損傷及び/又は化学的傷害を治療する方法であって、
トランス-立体異性体6-フェニルヘキサンアミド誘導体マイトフュージン活性化物質又はその薬学的に許容され得る塩のうちの1つ以上を含む治療有効量の組成物を被験体に投与する工程を含み、前記トランス-立体異性体6-フェニルヘキサンアミド誘導体マイトフュージン活性化物質は、ミトコンドリアの融合を刺激し、ミトコンドリアの健康状態を増進し、ミトコンドリアの細胞内移送を増強する、方法。 - R1が、独立して且つ必要に応じて、アセトアミド、C1-8アルコキシ、アミノ、アゾ、Br、C1-8アルキル、カルボニル、カルボキシル、Cl、シアノ、C3-8シクロアルキル、C3-8ヘテロアリール、C3-8ヘテロシクリル、ヒドロキシル、F、ハロ、インドール、N、ニトリル、O、フェニル、S、スルホキシド、二酸化硫黄及び/又はチオフェンのうちの1つ以上で置換され、R1が、必要に応じてさらに、1つ以上のアセトアミド、アルコキシ、アミノ、アゾ、Br、C1-8アルキル、カルボニル、カルボキシル、Cl、シアノ、C3-8シクロアルキル、C3-8ヘテロアリール、C3-8ヘテロシクリル、ヒドロキシル、F、ハロ、インドール、N、ニトリル、O、フェニル、S、スルホキシド、二酸化硫黄及び/又はチオフェンで置換され、前記アルキル、シクロアルキル、ヘテロアリール、ヘテロシクリル、インドール又はフェニル置換基のうちの1つ以上は、必要に応じてさらに、以下の置換基:アセトアミド、アルコキシ、アミノ、アゾ、Br、C1-8アルキル、カルボニル、カルボキシル、Cl、シアノ、C3-8シクロアルキル、C3-8ヘテロアリール、C3-8ヘテロシクリル、ヒドロキシル、F、ハロ、インドール、N、ニトリル、O、フェニル、S、スルホキシド、二酸化硫黄及びチオフェンのうちの1つ以上で置換される、請求項1又は2に記載の方法。
- 前記マイトフュージン活性化物質が、以下の化合物:
のうちの1つ以上を含む、請求項1~4のいずれかに記載の方法。 - 式II
Zは、シクロアルキル、ヘテロシクロアルキル、アリール又はヘテロアリールであり、
R2及びR3は、独立して、H、F、アルキル及びC3-7シクロアルキルから選択されるか、又はR2とR3とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
R4及びR5は、独立して、H、F、アルキル及びC3-7シクロアルキルから選択されるか、又はR4とR5とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
Yは、O、CR6R7、CR8=CR9、三重結合、シクロアルキル、ヘテロシクロアルキル、アリール、ヘテロアリール、NR8、S、SO2、SONR9、-NR9SO2-、-NR8CO-、-CONR8-又は-NR8CONR9-であり、R6は、H、F、アルキル及びシクロアルキルから選出され、R7は、H、F、アルキル及びシクロアルキルから選択されるか、又はR6とR7とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
R8は、H、アルキル及びC3-7シクロアルキルから選出され、
R9は、H、アルキル及びC3-7シクロアルキルから選択され、
oは、0、1、2、3、4又は5であり、
pは、0又は1であり、
qは、0、1、2、3、4又は5であり、oが、1以上であるとき、Y=NR8、S、SO2、SONR9、-NR9SO2-、-NR8CO-、-CONR8-、-NR8CONR9-であり、o+p+qの合計は、3以上又は7以下である、
化合物又はその薬学的に許容され得る塩。 - Zが、シクロアルキル、ヘテロシクロアルキル、アリール及びヘテロアリールであり、
Yが、O、CR6R7、シクロアルキル及びアリールであり、
R2、R3、R4、R5、R6、R7及びR8が、独立して、H及びアルキルから選択され、
oが、0、1、2、3、4又は5であり、
pが、0又は1であり、
qが、0、1、2、3、4又は5であり、
oが、1以上であるとき、Xは、S又はSO2であり、
o+p+qの合計は、3以上又は7以下である、
請求項6に記載の化合物又はその薬学的に許容され得る塩。 - Zが、アリール又はヘテロアリールであり、
Yが、O、CH2又はシクロアルキルであり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、
R9が、H、アルキル又はC3-7シクロアルキルであり、
oが、0、1、2、3、4又は5であり、
pが、0又は1であり、
qが、0、1、2、3、4又は5であり、
oが、1以上であるとき、Xは、S又はSO2であり、
o+p+qの合計は、3以上又は5以下である、
請求項6に記載の化合物又はその薬学的に許容され得る塩。 - Zが、アリール又はヘテロアリールであり、
Yが、シクロプロピル又はシクロブチルであり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、
R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
oが、0、1、2又は3であり、
pが、1であり、
qが、0、1、2又は3であり、
o+p+qの合計は、3以上又は5以下である、
請求項6に記載の化合物又はその薬学的に許容され得る塩。 - Zが、アリール又はヘテロアリールであり、
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、
R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
請求項6に記載の化合物又はその薬学的に許容され得る塩。 - Zが、アリール又はヘテロアリールであり、
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
請求項6に記載の化合物又はその薬学的に許容され得る塩。 - Zが、フェニル又はヘテロアリールであり、前記複素環式部分は、窒素、酸素及び硫黄から独立して選択される1~4個の原子を含み、前記フェニル又は複素環式部分は、R8、OR8、Cl、F、-CN、CF3、-NR8R9、-SO2NR8R9、-NR8SO2R9、-SO2R9、-CONR8R10、-NR8COR10、C3-7シクロアルキル及びヘテロシクロアルキルから独立して選択される0~4個の置換基を有し、
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
R10が、アルキル又はC3-7シクロアルキルであり、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
請求項6に記載の化合物又はその薬学的に許容され得る塩。 - Zが、フェニル又はヘテロアリールであり、前記複素環式部分は、窒素、酸素及び硫黄から独立して選択される1~3個の原子を含み、前記フェニル又は複素環式部分は、R8、OR8、Cl、F、-CN、CF3、-NR8R9、-SO2R9、-CONR8R9、-NR7COR10、C3-7シクロアルキル及びヘテロシクロアルキルから独立して選択される0~3個の置換基を有し、
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
R10が、アルキル又はC3-7シクロアルキルであり、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
請求項6に記載の化合物又はその薬学的に許容され得る塩。 - Zが、フェニル、2-ピリジニル、3-ピリジニル、4-ピリジニル、6-ピリミジニル、5-ピリミジニル、4-ピリミジニル又は2-ピリミジニルであり、前記フェニル、ピリジニル及びピリミジニル部分は、R8、OR8、Cl、F、-CN、CF3、-NR8R9、-SO2R10、-CONR8R9及び-NR8COR10から独立して選択される0~2個の置換基を有し、
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル及びC3-7シクロアルキルから選択され、
R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
R10が、アルキル又はC3-7シクロアルキルであり、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
請求項6に記載の化合物又はその薬学的に許容され得る塩。 - Zが、フェニル、2-ピリジニル、3-ピリジニル、4-ピリジニル、6-ピリミジニル、5-ピリミジニル、4-ピリミジニル又は2-ピリミジニルであり、前記フェニル、ピリジニル及びピリミジニル部分は、R8、OR8、Cl、F、-CN、CF3、-NR8R9、-SO2R10、-CONR8R9及び-NR8COR10から独立して選択される0~2個の置換基を有し、
Yが、O又はCH2であり、
R2、R3、R4及びR5が、CH2であり、
R8が、H、アルキル又はC3-7シクロアルキルであり、R9が、H、アルキル、COR7又はC3-7シクロアルキルであるか、又はR8とR9とが一体となって、C3-7シクロアルキルを形成し、
R10が、アルキル又はC3-7シクロアルキルであり、
oが、0、1、2、3又は4であり、
pが、1であり、
qが、0、1、2、3又は4であり、
o+p+qの合計は、5である、
請求項6に記載の化合物又はその薬学的に許容され得る塩。 - マイトフュージン活性化物質の必要を示す疾患を治療する方法であって、前記方法は、それを必要とする哺乳動物に治療有効量の式II
Zは、シクロアルキル、ヘテロシクロアルキル、アリール又はヘテロアリールであり、
R2及びR3は、独立して、H、F、アルキル及びC3-7シクロアルキルから選択されるか、又はR2とR3とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
R4及びR5は、独立して、H、F、アルキル及びC3-7シクロアルキルから選択されるか、又はR4とR5とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
Yは、O、CR6R7、CR8=CR9、三重結合、シクロアルキル、ヘテロシクロアルキル、アリール、ヘテロアリール、NR8、S、SO2、SONR9、-NR9SO2-、-NR8CO-、-CONR8-又は-NR8CONR9-であり、R6は、H、F、アルキル又はシクロアルキルであり、R7は、H、F、アルキル又はシクロアルキルであるか、又はR6とR7とが一体となって、C3-7シクロアルキル又はヘテロシクロアルキルを形成し、
R8は、H、アルキル又はC3-7シクロアルキルであり、
R9は、H、アルキル又はC3-7シクロアルキルであり、
oは、0、1、2、3、4又は5であり、
pは、0又は1であり、
qは、0、1、2、3、4又は5であり、oが、1以上であるとき、Y=NR8、S、SO2、SONR9、-NR9SO2-、-NR8CO-、-CONR8-、-NR8CONR9-であり、o+p+qの合計は、3以上又は7以下である、
方法。 - 前記PNS又はCNS障害が、
ミトコンドリアの融合、健康状態又は輸送が損なわれている慢性神経変性状態、
マイトフュージン1(MFN1)又はマイトフュージン2(MFN2)の機能不全に関連する疾患又は障害、
ミトコンドリアの断片化、機能不全又は運動不全に関連する疾患、
シャルコー・マリー・トゥース病、筋萎縮性側索硬化症、ハンチントン病、アルツハイマー病、パーキンソン病などの変性神経筋状態、
遺伝性運動感覚性ニューロパチー、自閉症、常染色体優性視神経萎縮症(ADOA)、筋ジストロフィー、ルー・ゲーリッグ病、癌、ミトコンドリアミオパチー、聴覚消失を伴う真性糖尿病(DAD)、レーベル遺伝性視神経症(LHON)、リー症候群、亜急性硬化性脳症、ニューロパチー・運動失調・網膜色素変性症・眼瞼下垂(NARP)、筋神経胃腸管性脳症(MNGIE)、赤色ぼろ線維・ミオクローヌスてんかん症候群(MERRF)、ミトコンドリアミオパチー・脳筋症・乳酸アシドーシス・脳卒中様症状(MELAS)、mtDNA枯渇、ミトコンドリア神経性胃腸管系脳筋症(MNGIE)、自律神経障害性ミトコンドリアミオパチー、ミトコンドリアチャネル病又はピルビン酸脱水素酵素複合体欠損症(PDCD/PDH)、
糖尿病性ニューロパチー、
化学療法誘発性末梢神経障害、並びに/又は
挫滅傷、脊髄傷害(SCI)、外傷性脳傷害、脳卒中、視神経傷害、及び軸索切断を伴う関連状態
のうちのいずれか1つ又は組み合わせから選択される、請求項1~5又は18のいずれかに記載の方法。 - 前記組成物が、薬学的に許容され得る賦形剤をさらに含む、請求項1~5又は18~20のいずれに記載の方法。
- CNS又はPNSの遺伝性又は非遺伝性の神経変性状態、傷害、損傷又は外傷を治療する方法であって、治療有効量の請求項6~17のいずれか1項に記載の化合物を前記被験体に投与する工程を含む、方法。
- 前記被験体が、
ミトコンドリアの融合、健康状態又は輸送が損なわれている慢性神経変性状態、
マイトフュージン1(MFN1)又はマイトフュージン2(MFN2)の機能不全に関連する疾患又は障害、
ミトコンドリアの断片化、機能不全又は運動不全に関連する疾患、
シャルコー・マリー・トゥース病、筋萎縮性側索硬化症、ハンチントン病、アルツハイマー病、パーキンソン病などの変性神経筋状態、
遺伝性運動感覚性ニューロパチー、自閉症、常染色体優性視神経萎縮症(ADOA)、筋ジストロフィー、ルー・ゲーリッグ病、癌、ミトコンドリアミオパチー、聴覚消失を伴う真性糖尿病(DAD)、レーベル遺伝性視神経症(LHON)、リー症候群、亜急性硬化性脳症、ニューロパチー・運動失調・網膜色素変性症・眼瞼下垂(NARP)、筋神経胃腸管性脳症(MNGIE)、赤色ぼろ線維・ミオクローヌスてんかん症候群(MERRF)、ミトコンドリアミオパチー・脳筋症・乳酸アシドーシス・脳卒中様症状(MELAS)、mtDNA枯渇、ミトコンドリア神経性胃腸管系脳筋症(MNGIE)、自律神経障害性ミトコンドリアミオパチー、ミトコンドリアチャネル病又はピルビン酸脱水素酵素複合体欠損症(PDCD/PDH)、
糖尿病性ニューロパチー、
化学療法誘発性末梢神経障害、並びに/又は
挫滅傷、脊髄傷害、外傷性脳傷害、脳卒中、視神経傷害、及び軸索切断を伴う関連状態
と診断されている又は有すると疑われる、請求項22に記載の方法。 - 請求項6~17のいずれか1項に記載の化合物及び薬学的に許容され得る賦形剤を含む、組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962797513P | 2019-01-28 | 2019-01-28 | |
US62/797,513 | 2019-01-28 | ||
US201962949060P | 2019-12-17 | 2019-12-17 | |
US62/949,060 | 2019-12-17 | ||
PCT/US2020/014784 WO2020159797A1 (en) | 2019-01-28 | 2020-01-23 | Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022523702A true JP2022523702A (ja) | 2022-04-26 |
JPWO2020159797A5 JPWO2020159797A5 (ja) | 2023-06-05 |
Family
ID=71841885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021543502A Pending JP2022523702A (ja) | 2019-01-28 | 2020-01-23 | トランス-4-ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11083699B2 (ja) |
EP (1) | EP3917509A4 (ja) |
JP (1) | JP2022523702A (ja) |
AU (1) | AU2020215510A1 (ja) |
CA (1) | CA3127453A1 (ja) |
WO (1) | WO2020159797A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11760733B2 (en) * | 2017-04-23 | 2023-09-19 | Washington University | Small molecule regulators of mitochondrial fusion and methods of use thereof |
WO2020159797A1 (en) * | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof |
CN117377652A (zh) * | 2021-03-19 | 2024-01-09 | 线粒体情感状态公司 | N-(反式-4-羟基环己基)-6-苯基己酰胺的环丙烷类似物和相关化合物 |
WO2022204125A1 (en) | 2021-03-22 | 2022-09-29 | Mitochondria Emotion, Inc. | Polymorphic forms of n-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide |
WO2023014828A2 (en) | 2021-08-03 | 2023-02-09 | Mitochondria Emotion, Inc. | Cyclopentane and cyclohexane variants of 6-phenylhexanamide mitofusin activators and methods for use thereof |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4466977A (en) | 1981-04-09 | 1984-08-21 | The Upjohn Company | N-[2-Amino(oxy- or thia- group-substituted-cycloaliphatic)]benzeneacetamides and -benzamide analgesics |
US4438130A (en) | 1981-11-12 | 1984-03-20 | The Upjohn Company | Analgesic 1-oxa-, aza- and thia-spirocyclic compounds |
US4463013A (en) | 1982-04-09 | 1984-07-31 | The Upjohn Company | Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs |
US4656182A (en) | 1983-12-06 | 1987-04-07 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
US4588591A (en) | 1984-05-25 | 1986-05-13 | The Upjohn Company | Analgesic 2-oxa-spirocyclic compounds |
US4632935A (en) | 1984-05-30 | 1986-12-30 | The Upjohn Company | Omega-(hydroxy-, ether and ester)-alkyl-2-amino-cycloalkyl- and cycloalkenyl amides as analgesics |
US4618621A (en) | 1984-09-21 | 1986-10-21 | The Upjohn Company | Method for treating medical conditions involving cerebral ischemia |
US4677122A (en) | 1984-11-13 | 1987-06-30 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
US4737493A (en) | 1985-07-01 | 1988-04-12 | Warner-Lambert Company | 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro(4,5)decanes as analgesic agents |
US4801604A (en) | 1985-10-25 | 1989-01-31 | The Upjohn Company | Cis-N-(2-aminocycloaliphatic)benzamide anti-convulsants |
US4855316A (en) | 1988-02-18 | 1989-08-08 | Warner-Lambert Company | 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds |
US5051428A (en) | 1988-12-06 | 1991-09-24 | Warner-Lambert Company | 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics |
US5063242A (en) | 1989-04-21 | 1991-11-05 | Warner-Lambert Company | 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino-1-oxaspiro[4,5]decanes as diuretics antiinflammatory, and cerebrovascular agents |
US5366987A (en) | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
FR2734815B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes arylalkyl (thio) carboxamides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
US6127159A (en) | 1997-06-06 | 2000-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Mitofusin genes and their uses |
WO2001025274A1 (en) | 1999-10-06 | 2001-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | Mitofusins, fzo homologs and functional derivatives thereof |
MXPA05006487A (es) * | 2002-12-17 | 2005-08-26 | Pfizer | Compuestos cicloalquilenamida como antagonistas de receptor nr2b. |
JP4675330B2 (ja) | 2003-11-14 | 2011-04-20 | デューク ユニバーシティ | シャルコー・マリー・ツース病2a型の検出方法 |
AU2005295167B2 (en) | 2004-10-20 | 2012-05-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
US8361439B1 (en) | 2005-01-04 | 2013-01-29 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8791069B1 (en) | 2005-01-04 | 2014-07-29 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8574544B1 (en) | 2005-01-04 | 2013-11-05 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8354094B1 (en) | 2005-01-04 | 2013-01-15 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8226928B1 (en) | 2011-06-17 | 2012-07-24 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
EP2066329B1 (en) | 2006-09-15 | 2017-09-06 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cyclobutylmethylamines |
US8604244B2 (en) | 2010-07-02 | 2013-12-10 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
WO2008091710A2 (en) | 2007-01-26 | 2008-07-31 | Washington University | Methods and compositions for treating neuropathies |
EP2200653A2 (en) | 2007-09-10 | 2010-06-30 | University of Massachusetts | Mitochondria-targeted anti-tumour agents |
WO2009114700A2 (en) | 2008-03-12 | 2009-09-17 | The Trustees Of Columbia University In The City Of New York | Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion |
US20110256565A1 (en) | 2008-05-30 | 2011-10-20 | Schon Eric A | Methods for diagnosis and treatment of neurodegenerative diseases or disorders |
MX2010013353A (es) | 2008-06-04 | 2010-12-21 | Astrazeneca Ab | Nuevos compuestos vii. |
WO2011053825A2 (en) | 2009-10-30 | 2011-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment or prevention of mitochondrial diseases |
WO2011133879A2 (en) | 2010-04-22 | 2011-10-27 | University Of Massachusetts | Combination therapies with mitochondrial-targeted anti-tumor agents |
SG10201602286RA (en) | 2010-12-23 | 2016-04-28 | Amazentis Sa | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders |
WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
WO2012158624A2 (en) | 2011-05-13 | 2012-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of mitochondrial fission and methods of use thereof |
US10132817B2 (en) | 2011-07-12 | 2018-11-20 | Rowan University | Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease |
US9238625B2 (en) | 2011-12-30 | 2016-01-19 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives |
JP6253596B2 (ja) | 2012-02-16 | 2017-12-27 | ザ ペン ステイト リサーチ ファンデーション | アシル補酵素a:リゾカルジオリピン・アシル基転移酵素1(alcat1)の発現、機能または活性の阻害物質を同定する方法 |
MX364547B (es) | 2012-07-12 | 2019-04-30 | Khondrion Ip B V | Derivados de cromanil para tratar enfermedad mitocondrial. |
WO2014059115A1 (en) | 2012-10-10 | 2014-04-17 | University Of Washington Through Its Center For Commercialization | Compositions and methods for diagnosis and treatment of neurological disease |
WO2014089017A1 (en) | 2012-12-03 | 2014-06-12 | Vascular Biosciences | Methods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis |
WO2014124458A1 (en) | 2013-02-11 | 2014-08-14 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases |
AU2014317884B2 (en) | 2013-09-09 | 2017-09-07 | Canimguide Therapeutics Ab | Immune system modulators |
US20150168379A1 (en) | 2013-12-12 | 2015-06-18 | Macau University Of Science And Technology | Method of identifying and screening drug candidate for preventing and/or treating ischemic myocardial disease |
EP3895705A3 (en) | 2013-12-20 | 2022-03-09 | University of Manitoba | Methods and compositions for treatment of peripheral neuropathies |
JP2017512068A (ja) | 2014-02-17 | 2017-05-18 | ネステク ソシエテ アノニム | マイトフュージンの方法及び使用 |
WO2015142001A2 (ko) * | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
NZ724799A (en) | 2014-04-16 | 2023-07-28 | Sujon Pty Ltd | Compositions and methods for the treatment or prevention of neurodegenerative disorders |
EP3154999A1 (en) | 2014-06-10 | 2017-04-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases |
WO2016022914A1 (en) | 2014-08-08 | 2016-02-11 | Moderna Therapeutics, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
WO2016029027A2 (en) | 2014-08-21 | 2016-02-25 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention and treatment of disease |
US20180028520A1 (en) | 2014-09-30 | 2018-02-01 | The Trustees Of Columbia University In The City Of New York | Methods and pharmaceutical compositions for treatment of amyotrophic lateral sclerosis |
US9865522B2 (en) | 2014-11-18 | 2018-01-09 | International Business Machines Corporation | Composite heat sink structures |
KR101647030B1 (ko) | 2014-11-20 | 2016-08-09 | 한국생명공학연구원 | 미토푸신 억제제를 포함하는, 세포 리프로그래밍 촉진용 조성물 및 이의 용도 |
WO2016115632A1 (en) | 2015-01-21 | 2016-07-28 | Exerkine Corporation | Method for treating mitochondrial disease |
US20180015098A1 (en) | 2015-02-03 | 2018-01-18 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
US10143719B2 (en) | 2015-02-06 | 2018-12-04 | Case Western Reserve University | Inhibitors of valosin-containing protein and methods of use |
WO2016161294A1 (en) | 2015-04-02 | 2016-10-06 | Salk Institute For Biological Studies | Err alpha and err gamma are essential coordinators of cardiac metabolism and function |
JP6914858B2 (ja) | 2015-06-15 | 2021-08-04 | ラッシュ・ユニバーシティ・メディカル・センター | 脳由来のPPARαリガンド |
EP3800186A1 (en) | 2015-07-14 | 2021-04-07 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
US10815211B2 (en) | 2015-10-08 | 2020-10-27 | Khondrion Ip B.V. | Compounds for treating mitochondrial disease |
EP3395019B1 (en) | 2015-12-21 | 2022-03-30 | Google LLC | Automatic suggestions and other content for messaging applications |
GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
WO2018013811A1 (en) | 2016-07-14 | 2018-01-18 | The Regents Of The University Of California | Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders |
AU2017302672A1 (en) | 2016-07-28 | 2019-02-14 | Mayo Foundation For Medical Education And Research | Small molecule activators of parkin enzyme function |
AU2017306676B2 (en) | 2016-08-03 | 2024-02-22 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
KR101872105B1 (ko) | 2016-09-05 | 2018-06-27 | 사회복지법인 삼성생명공익재단 | 샤르코 마리 투스병 치료용 약학 조성물 |
US10578610B2 (en) | 2016-09-20 | 2020-03-03 | Washington University | Peptide regulators of mitochondrial fusion and methods of use |
US10987367B2 (en) | 2016-11-28 | 2021-04-27 | Texas Tech University System | Drug targets of delayed aging and human brain diseases |
EP3548039B1 (en) | 2016-12-04 | 2023-07-19 | Alavi Khorassani Moghadam, Marcel Victor | Ribavirin for use in the treatment of a mitochondrial disease |
BR112019020252A2 (pt) | 2017-03-31 | 2020-04-22 | Perenna Pharmaceuticals Inc | compostos úteis como inibidores de alcat 1 |
US20200054718A1 (en) | 2017-04-05 | 2020-02-20 | Lara S Milane | EGFR/MFN2 Targeted Nanoparticles Particularly Useful For Treating Multidrug Resistant Triple Negative Breast Cancer Through Mitochondrial Fusion Inhibition |
US11760733B2 (en) | 2017-04-23 | 2023-09-19 | Washington University | Small molecule regulators of mitochondrial fusion and methods of use thereof |
GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
US20210128596A1 (en) | 2017-09-27 | 2021-05-06 | University Of Pennsylvania | Compositions and methods for treating septic cardiomyopathy |
WO2019068865A1 (en) | 2017-10-06 | 2019-04-11 | Universiteit Antwerpen | BIOMARKERS FOR NEURODEGENERATIVE AND / OR NEUROMUSCULAR DISEASES |
US11813268B2 (en) | 2017-10-17 | 2023-11-14 | Albert Einstein College Of Medicine | Mitofusin activators and uses thereof |
US10660873B2 (en) | 2018-02-23 | 2020-05-26 | University Of South Florida | ALDA-1 treatment and prevention of pulmonary disease |
CN112469475A (zh) | 2018-04-20 | 2021-03-09 | 泰莱托恩基金会 | miR-181抑制剂及其用途 |
EP3575401A1 (en) | 2018-05-29 | 2019-12-04 | Ecole Polytechnique Federale De Lausanne (Epfl) | Methods of treating or preventing an aging-related disease |
WO2019234664A1 (en) | 2018-06-06 | 2019-12-12 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
WO2020030954A1 (en) | 2018-08-09 | 2020-02-13 | Integrative Medicine Clinic, Sia | Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer |
WO2020112565A1 (en) | 2018-11-29 | 2020-06-04 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of mitofusion 1 and beta ii pkc association for treating heart failure |
EP3917508A4 (en) * | 2019-01-28 | 2022-12-21 | Mitochondria Emotion, Inc. | EAAT2 ACTIVATORS AND METHODS OF USE THEREOF |
WO2020159797A1 (en) * | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof |
-
2020
- 2020-01-23 WO PCT/US2020/014784 patent/WO2020159797A1/en unknown
- 2020-01-23 EP EP20748001.3A patent/EP3917509A4/en active Pending
- 2020-01-23 AU AU2020215510A patent/AU2020215510A1/en active Pending
- 2020-01-23 JP JP2021543502A patent/JP2022523702A/ja active Pending
- 2020-01-23 CA CA3127453A patent/CA3127453A1/en active Pending
- 2020-07-22 US US16/935,557 patent/US11083699B2/en active Active
-
2021
- 2021-04-30 US US17/245,388 patent/US20210251925A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11083699B2 (en) | 2021-08-10 |
CA3127453A1 (en) | 2020-08-06 |
WO2020159797A1 (en) | 2020-08-06 |
EP3917509A1 (en) | 2021-12-08 |
US20200345668A1 (en) | 2020-11-05 |
US20210251925A1 (en) | 2021-08-19 |
EP3917509A4 (en) | 2022-11-09 |
AU2020215510A1 (en) | 2021-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022523702A (ja) | トランス-4-ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法 | |
US10351514B2 (en) | Benzimidazole inhibitors of the sodium channel | |
JP2022518632A (ja) | マイトフュージン活性化物質及びその使用方法 | |
US9926299B2 (en) | Inhibitors of bruton's tyrosine kinase | |
ES2353247T3 (es) | Derivados de (1h-indol-7-il)-pirimidin-2-il-amino)metadona y compuestos emparentados como inhibidores del igf-ri, para el tratamiento de cancer. | |
US8133998B2 (en) | Bicyclic pyrimidine derivatives as calcium channel blockers | |
JP2018508525A (ja) | リルゾールプロドラッグおよびそれらの使用 | |
US20080227823A1 (en) | Amide derivatives as calcium channel blockers | |
US20220362229A1 (en) | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | |
AU2019253831B2 (en) | Compositions and methods for treating neurodegenerative diseases | |
BR112019014235A2 (pt) | Inibidores bicíclicos de histona desacetilase | |
CN102686578A (zh) | Pde4的双环杂芳基抑制剂 | |
CN102834389A (zh) | 二聚化iap抑制剂 | |
US8765953B2 (en) | Compounds and methods for the treatment of pain and other diseases | |
US20160016939A1 (en) | Heterocyclic inhibitors of the sodium channel | |
KR20130118731A (ko) | 항증식성 질환 치료에 사용하기 위한 pi3k 억제제로서 피페라지노트리아진 | |
US20070112043A1 (en) | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | |
WO2004060400A1 (ja) | 上皮成長因子受容体を分子標的とする抗精神病薬 | |
US8530453B2 (en) | Compounds and methods for the treatment of pain and other diseases | |
CN111433185A (zh) | 钾离子及trpv1通道的调节剂及其用途 | |
CN113272292B (zh) | (2,5-二氧代吡咯烷-1-基)(苯基)-乙酰胺衍生物及其在治疗神经系统疾病中的用途 | |
US20210323930A1 (en) | Voltage-dependent t-type calcium channel inhibitor | |
US11839659B2 (en) | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein | |
CN117377652A (zh) | N-(反式-4-羟基环己基)-6-苯基己酰胺的环丙烷类似物和相关化合物 | |
US20230150990A1 (en) | Sphk inhibitors and methods of making and using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230526 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240123 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240423 |